HKSE - Delayed Quote HKD

SHANDONG XINHUA (0719.HK)

Compare
5.540
-0.070
(-1.25%)
At close: 4:08:28 PM GMT+8

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Mr. Tongqing He Chairman & Deputy GM 1.71M -- 1970
Mr. Wenhui Xu GM & Executive Director 1.62M -- 1977
Mr. Ning Hou CFO, Financial Controller & Executive Director 1.36M -- 1974
Mr. Zhonghui Zheng Deputy General Manager -- -- 1972
Mr. Changsheng Wei Deputy GM & Manager of Administrative Personnel Department -- -- 1971
Mr. Xuesong Liu Deputy General Manager -- -- 1985
Mr. Changqiu Cao Company Secretary -- -- 1970
Mr. Zuxing Kou Deputy General Manager -- -- 1982
Ms. Haifeng Guo Head of Accounting Department -- -- --
Mr. Xiaohong He Chief of Finance Department -- -- --

SHANDONG XINHUA

No. 1 Lutai Avenue
High-tech Industry Development Zone
Zibo, 255086
China
86 53 3216 6666 https://www.xhzy.com
Sector: 
Healthcare
Full Time Employees: 
7,104

Description

Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. The company was founded in 1943 and is based in Zibo, the People's Republic of China.

Corporate Governance

SHANDONG XINHUA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 26, 2025 at 10:59 AM UTC - March 31, 2025 at 12:00 PM UTC

SHANDONG XINHUA Earnings Date

Recent Events

September 4, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers